Form 4: AEON Biopharma Executive Granted Over 1.3 Million Restricted Stock Units

AEON Biopharma, Inc.'s Executive Vice President, Chief Legal Officer, and Corporate Secretary, Alexander Blair Wilson, was granted 1,316,872 Restricted Stock Units as part of executive compensation.

Summary

• Alexander Blair Wilson, Executive VP, CLO & Corporate Secretary of AEON Biopharma, Inc. (AEON), was granted 1,316,872 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was May 21, 2025.
• Each RSU will be settled in cash based on the fair market value of AEON's Class A Common Stock on the applicable vesting date.
• The RSUs will vest over four years, with 25% vesting on each anniversary of May 21, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects a standard executive compensation grant, aligning the executive's interests with the company's long-term performance. It does not, however, indicate any new operational achievements or financial results.

Positives

• The grant of Restricted Stock Units to a key executive aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This represents a significant equity stake for the Executive VP, CLO & Corporate Secretary, potentially incentivizing long-term commitment and performance.

Future Outlook

The vesting schedule indicates that 25% of the granted RSUs will vest annually starting from May 21, 2025, over the next four years, providing a future stream of compensation tied to the company's stock performance.

Management Comments

• Each restricted stock unit ("RSU") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date.
• 25% of the RSUs shall vest on each anniversary of May 21, 2025.

Industry Context

The grant of Restricted Stock Units is a common practice in the biopharmaceutical industry and across various sectors for executive compensation, aiming to attract, retain, and incentivize key talent by aligning their financial interests with the long-term performance of the company's stock.

Comparison to Industry Standards

• The grant of Restricted Stock Units with a multi-year vesting schedule is a standard form of long-term incentive compensation for executives across industries, including biopharma.
• The structure of tying compensation to future stock performance through RSUs is widely adopted by companies like Pfizer, Johnson & Johnson, and Amgen for their senior leadership to promote shareholder alignment.

Related Party Transactions

• The transaction involves the grant of Restricted Stock Units to a key executive, Alexander Blair Wilson, which is a form of compensation and an insider transaction.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the executive's financial interests with shareholder value creation, potentially leading to more focused long-term performance.
• Employees: This compensation structure for a senior executive may set a precedent or reflect the company's overall compensation philosophy.

Next Steps

• Future vesting events for the Restricted Stock Units will occur annually on May 21st, starting in 2026.

Key Dates

Keywords

AEON Biopharma, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Alexander Wilson, Biopharma, Equity Grant